Re-evaluating Chronic Hepatitis B Treatment in the Grey Zone

Clinicians worldwide face major clinical dilemmas when managing indeterminate phase patients who fall outside conventional management protocols. Historically, professional guidelines reserved chronic hepatitis B treatment for patients demonstrating elevated alanine aminotransferase levels and high viral loads. However, nearly one-third of infected individuals occupy an indeterminate phase commonly designated as the grey zone. These patients show fluctuating viral replication and borderline hepatic enzyme levels, creating diagnostic ambiguity. Consequently, practitioners often defer antiviral therapy while observing progressive hepatic inflammation. Recent epidemiological observations indicate that untreated grey zone individuals face substantial risks of disease progression. Furthermore, their long-term risk of hepatocellular carcinoma significantly exceeds that of inactive carriers. Therefore, maintaining strict exclusionary thresholds creates unintended clinical risks for patients with silent liver injury. Clinicians now recognise that withholding therapy solely due to arbitrary biochemical cutoffs compromises patient safety. In response, international experts urge a critical reassessment of traditional treatment candidacy. By shifting attention toward early viral suppression, clinicians can halt occult fibrotic progression before permanent parenchymal remodeling develops. Moreover, non-invasive fibrosis testing clarifies risk stratification in this ambiguous cohort.

Clinical Hazards of Persistent Viremia and Silent Disease Progression

Although conventional protocols categorize indeterminate patients as low risk, prolonged viral replication drives continuous subclinical inflammation. Specifically, persistent circulating viral DNA triggers ongoing immune-mediated injury even when serum transaminases appear normal. As a result, many patients accumulate significant histological fibrosis without manifesting overt biochemical abnormalities. Cohort analyses demonstrate that sustained viremia increases the cumulative incidence of cirrhosis and liver decompensation over time. Furthermore, oncogenic viral integration occurs continuously during active replication, promoting genomic instability. Consequently, grey zone patients face an elevated lifetime risk of malignant transformation compared to inactive carriers. Older age, male sex, and prolonged infection duration further amplify these oncogenic hazards. In addition, concurrent metabolic comorbidities like non-alcoholic fatty liver disease accelerate fibrotic progression synergistically. Therefore, relying solely on transaminase levels often conceals advancing microvascular and parenchymal damage. Clinicians must acknowledge that normal transaminases never guarantee histological quiescence. Routine liver biopsies frequently reveal moderate necroinflammatory activity in indeterminate individuals. Hence, early therapeutic intervention provides crucial parenchymal preservation.

Evidence Supporting Early Antiviral Intervention Across High-Risk Groups

Compelling data from prospective registries, retrospective cohorts, and clinical trials confirm the therapeutic value of early intervention. Specifically, initiating nucleos(t)ide analogues in grey zone patients significantly lowers the incidence of liver-related clinical events. Furthermore, modern antiviral regimens drastically reduce hepatocellular carcinoma rates in patients who achieve sustained virological suppression. Recent multicenter studies identify distinct high-risk patient subgroups that derive profound benefits from prompt therapy. In particular, older patients, individuals with thrombocytopenia, and hepatitis B e-antigen-positive patients experience dramatic outcome improvements. For instance, low platelet counts often indicate occult portal hypertension and bridging fibrosis, necessitating immediate viral suppression. Moreover, early antiviral therapy prevents biochemical flare-ups and histological decompensation before clinical crises emerge. In contrast, conservative surveillance frequently fails because patients suffer sudden, unpredictable hepatic flares. Therefore, treating patients before biochemical decompensation occurs represents a far safer clinical strategy. By deploying potent oral antivirals proactively, physicians secure durable viral control and prevent neoplastic transformation. Extensive meta-analyses corroborate that prompt viral clearance correlates with regression of early-stage liver fibrosis.

Navigating Practical Challenges: Adherence, Cost, and Drug Resistance

Expanding therapeutic eligibility to broader cohorts introduces tangible healthcare challenges that practitioners must navigate effectively. Foremost among these concerns is the lifelong commitment to oral therapy, which increases overall pill burden. Consequently, long-term patient adherence may decline over extended follow-up, potentially prompting viral breakthrough or rebound hepatitis. Furthermore, premature therapy discontinuation elevates the risk of severe acute flare-ups and hepatic decompensation. Fortunately, contemporary oral agents like tenofovir disoproxil fumarate, tenofovir alafenamide, and entecavir exhibit high genetic barriers to resistance. Thus, drug resistance rarely develops when patients maintain consistent therapy. Nonetheless, medication affordability and healthcare access remain major barriers, especially across resource-limited environments. Many insurance programs currently restrict medication reimbursement to patients meeting rigid biochemical criteria. Therefore, expanding treatment indications necessitates policy adjustments to subsidize essential medications and monitoring tests. Moreover, clinical teams must deliver comprehensive patient counseling regarding adherence and therapeutic safety. Through systematic patient education and accessible pricing structures, healthcare systems can safely implement broader antiviral access without compromising compliance.

Aligning Clinical Practice with WHO 2030 Elimination Milestones

The World Health Organization has established rigorous global targets aiming to eliminate viral hepatitis by the year 2030. These ambitious benchmarks require reducing new hepatitis infections by ninety percent and liver-related mortality by sixty-five percent. However, the international medical community cannot attain these crucial targets under outdated, restrictive treatment guidelines. In fact, fewer than fifteen percent of eligible chronic hepatitis patients globally receive necessary antiviral medications today. By restricting therapy to end-stage or overtly inflamed disease, clinicians miss a critical window for intervention. Consequently, expanding treatment criteria to encompass indeterminate and grey zone individuals serves as an essential public health intervention. Updated global recommendations now endorse simplified treatment algorithms, lowering viral load cutoffs and minimizing complex monitoring barriers. Furthermore, broader eligibility streamlines decentralized service delivery within primary healthcare frameworks across developing nations. Therefore, adopting inclusive treatment criteria bridges the massive gap between diagnosed patients and therapeutic provision. Ultimately, proactive intervention preserves liver function, curbs viral transmission, and accelerates collective progress toward global viral hepatitis elimination.

What defines the grey zone in chronic hepatitis B infection?

The grey zone encompasses chronic hepatitis B patients whose clinical profiles do not conform to traditional immune-tolerant, immune-active, or inactive carrier stages. Specifically, these individuals demonstrate fluctuating viral loads alongside normal or borderline alanine aminotransferase levels. Because they lack overt biochemical inflammation or definitive cirrhosis, conventional guidelines historically excluded them from therapy. However, histological evaluations frequently reveal significant underlying fibrosis and necroinflammation, placing these individuals at substantial risk for disease progression.

Why is early antiviral treatment recommended for indeterminate patients?

Early antiviral intervention effectively suppresses viral replication and halts progressive hepatocyte injury before permanent histological scarring occurs. Clinical trials demonstrate that treating indeterminate patients substantially lowers the long-term incidence of cirrhosis, hepatic decompensation, and hepatocellular carcinoma. Furthermore, high-risk subsets—such as individuals with low platelet counts or advanced age—experience significant survival benefits from prompt therapy. Consequently, initiating treatment prevents unpredictable acute biochemical flares and preserves overall functional hepatic reserve.

How do newer guidelines address adherence and medication resistance risks?

Modern clinical guidelines advocate utilizing first-line nucleos(t)ide analogues with exceptionally high barriers to genetic resistance, such as entecavir and tenofovir formulations. Consequently, resistance mutations remain exceptionally rare even during decades of continuous administration. To address adherence and cost concerns, guidelines endorse simplified dosing schedules, decentralized delivery through community clinics, and expanded access to generic formulations. Moreover, routine patient counseling and structured monitoring protocols ensure excellent long-term compliance and safety.

Disclaimer: This content is for informational and educational purposes only. It is not intended to substitute for professional medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Lin CL et al. Expanding treatment guidelines for chronic hepatitis B: A narrative review. J Formos Med Assoc. 2026 Sep 15. doi: undefined. PMID: 42744736.


2. World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Geneva: World Health Organization; 2024.


3. Ghany MG, Pan CQ, Lok AS, et al. AASLD/IDSA Practice Guideline on treatment of chronic hepatitis B. Hepatology. 2025; 82(5): 1020-1045.


4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2025; 82(3): 510-538.